House Dust Mite Allergy Completed Phase 2 Trials for Tregalizumab (DB13073)

Also known as: Allergic Rhinitis Due to House Dust Mite / Allergy to House Dust / Allergy to House Dust Mite / Dust Mite Allergy / Allergy to dust mite protein (finding) / Allergic rhinitis caused by house dust mite (disorder) / House dust allergy / Allergy to house dust (finding) / Mite allergy

IndicationStatusPhase
DBCOND0033667 (House Dust Mite Allergy)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04673591Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic PatientsTreatment